TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06138951

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endurance exercise
Description: On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
Study: NCT00399984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Education Program
Description: interactive seminars regarding daily inhaled corticosteroids
Study: NCT00853684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
Study: NCT00663156

Intervention type: PROCEDURE
Group type: OTHER
Intervention: breast implants
Description: patients will have breast augmentation using implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction, fat grafting
Description: Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
Study: NCT00932607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual immunotherapy
Description: Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual immunotherapy
Description: Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy).
Study: NCT04031417

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia

Intervention type: OTHER
Group type: OTHER
Intervention: Low Humidity

Intervention type: OTHER
Group type: OTHER
Intervention: Low Humidity

Intervention type: OTHER
Group type: OTHER
Intervention: Low Humidity
Study: NCT00343824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aquacel AG hydrofiber versus acticoat burn dressing
Description: Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
Study: NCT04284553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified
Description: The alert language itself will be simplified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified
Description: The alert language itself will be simplified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sign-off alert
Description: An alert will display in the electronic health record when the medication is sent to sign-off for providers.
Study: NCT04284553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sign-off alert
Description: An alert will display in the electronic health record when the medication is sent to sign-off for providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-commitment
Description: A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-commitment
Description: A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different Risks
Description: Risks of the high-risk medications will be framed differently.
Study: NCT00677248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe and placebo
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome and ezetimibe
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment
Study: NCT03119129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ho'ouna Pono Drug Prevention Curriculum
Description: Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ho'ouna Pono Drug Prevention Curriculum
Description: Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
Study: NCT00677248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome and ezetimibe
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome and ezetimibe
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment
Study: NCT03686813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Oral sildenafil, 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT03640273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prapchompoothaweep remedy
Description: Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 Mg
Description: Take Loratadine 10 mg once a day before meals.
Study: NCT00835016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early psychosocial stimulation (LTP)
Description: Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early psychosocial stimulation (LTP)
Description: Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
Study: NCT01942083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Study: NCT03429387

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Description: FDG-PET performed with low dose CT
Study: NCT05428072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar test
Description: All participants will take two sugar tests ( sugar cocktail consisting of mannitol \& lactulose) subjects within 2-3 days of the initial sugar test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Challenge
Description: All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 \& 1 hour before the sugar drink.
Study: NCT03429387

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CT
Description: HRCT and CT of sinuses +/- other regions as per clinician's discretion
Study: NCT02414230

Intervention type: DRUG
Intervention: Drug: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT04284553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different Risks
Description: Risks of the high-risk medications will be framed differently.
Study: NCT01720446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
Study: NCT00694512

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low fat diet
Description: 20% fat diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fat diet
Description: 40% fat diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT diet
Description: Medium chain triglyceride diet
Study: NCT02244450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCID screening
Study: NCT00808691

Intervention type: OTHER
Intervention: Critical care
Description: Standard care for each group of patients

Intervention type: OTHER
Intervention: Critical care
Description: Standard care for each group of patients

Intervention type: OTHER
Intervention: Critical care
Description: Standard care for each group of patients

Intervention type: OTHER
Intervention: Critical care
Description: Standard care for each group of patients

Intervention type: OTHER
Intervention: Critical care
Description: Standard care for each group of patients

Intervention type: OTHER
Intervention: Critical care
Description: Standard care for each group of patients
Study: NCT01720446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
Study: NCT01379534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT04285346

Intervention type: DRUG
Group type: OTHER
Intervention: Ganaxolone
Description: titration followed by maintenance and extension period
Study: NCT06269341

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03823417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion
Study: NCT03957681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Description: 210 mg Q2W, SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Q2W, SC
Study: NCT05118958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet
Study: NCT01720446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
Study: NCT05118958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet
Study: NCT01004328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1: Electronic medical record (EMR)-based transitional care intervention
Description: Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
Study: NCT03837769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia OBPM PulseWatch wrist device
Description: The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
Study: NCT04284553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Epic Basic Alert
Description: This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
Study: NCT05118958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet
Study: NCT00853424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: islet cell transplant
Description: Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: subjects receive all recommended medical treatment for diabetes and diabetic eye disease
Study: NCT05118958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 2 modified-release tablet
Description: 300 mg modified-release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KVD824 Immediate-Release Capsule
Description: 300 mg immediate-release capsule
Study: NCT00452465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ElderCare Plan
Description: Nursing assessment and development of an appropriate care plan.
Study: NCT04726046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotetan
Description: Cefotetan (as Disodium) 1 GM Injection before surgery
Study: NCT00067639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (Neulasta)
Description: 12 mg single injection of pegfilgrastim under the skin prior to apheresis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
Study: NCT05118958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to KVD824 Prototype 1
Description: Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
Study: NCT04552522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shrimp allergy with intend to eat shrimp
Description: shrimp allergy with intend to eat shrimp and treat with oral immunotherapy
Study: NCT03494686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLETZ under local anaesthesia
Description: Conization will be performed under local anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ under general anaesthesia
Description: Conization will be performed under general anaesthesia
Study: NCT01947309

Intervention type: DRUG
Intervention: Revlimid (lenalidomide)
Description: Revlimid (lenalidomide) as prescribed in usual clinical practice
Study: NCT01751880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity intervention
Description: Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
Study: NCT01659294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Case Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard diabetologist care
Description: routine care by diabetologist \& team
Study: NCT05349604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic extracts
Description: One intake in total
Study: NCT01259765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VHH batch 203027
Description: The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
Study: NCT03100097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen Horizon 627 LSO
Study: NCT05118958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to KVD824 Prototype 1
Description: Placebo to 300 mg KVD824 Prototype 1 modified-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 3 modified-release tablet
Description: 300 mg modified-release tablet
Study: NCT00231842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
Study: NCT02773914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Comprehensive Geriatric Assessment intervention
Study: NCT03582033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-BCMA
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-BCMA
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-BCMA
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given by mouth (orally) or by IV
Study: NCT00231842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
Study: NCT03582033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given by mouth (orally) or by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Given orally
Study: NCT04417621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: LXH254 will be supplied as tablet for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: LTT462 will be supplied as hard gelatin capsule for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be supplied as film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib will be supplied in tablets and hard gelatin capsules.
Study: NCT04159610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3970
Description: Application of cream to each axilla

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
Description: Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only